Highlights

  • Third quarter 2026 net loss was $22,271 thousand, compared with $13,779 thousand a year earlier, with no collaboration revenue.
  • The company closed its initial public offering on August 6, 2026, with net proceeds of approximately $305.3 million.
  • Cash, cash equivalents and marketable securities were $395.9 million at quarter end, which the company estimates funds operations into 2030.
  • ATTO-2306 and ATTO-1091 are in IND-enabling studies, with Phase 1 trials expected to begin in the first half of 2027.

Attovia Therapeutics, Inc. (NASDAQ:ATTO) shares were trading at USD 14.75 on November 17, 2026, up 0.17%, with a relative Volume at time of 1.84. The clinical-stage biopharmaceutical company completed its initial public offering on August 6, 2026, and filed its Quarterly Report for the period ended September 30, 2026 on November 9.

Attovia is a Delaware corporation headquartered in San Carlos, California, incorporated in December 2022, with a fiscal year ending December 31. It develops biotherapeutics for immune-mediated diseases using its ATTOBODY biparatopic Biologics platform, which it in-licensed from Alamar Biosciences, Inc. Its pipeline includes ATTO-1310, an interleukin-31 therapeutic that completed Phase 1 dosing in the first quarter of 2026, ATTO-2306, an IL-13 and IL-31 bispecific, and ATTO-1091, a trispecific Fc fusion protein designed to block TL1A, IL-23 and integrin α4ß7. It had 50 full-time employees as of September 30, 2026, and 45,712,536 shares of common stock outstanding as of October 31, 2026.

Initial Public Offering

The registration statement for the offering became effective on August 4, 2026, and the offering closed on August 6, 2026. Attovia issued 19,550,000 shares of common stock at $17.00 per share, including 2,550,000 shares from the underwriters' option, for gross proceeds of $332.4 million and net proceeds of approximately $305.3 million. On closing, all redeemable convertible preferred stock converted into 21,517,976 shares of common stock. The company reported no material change in its planned use of proceeds.

Third Quarter Results

For the three months ended September 30, 2026, Attovia reported a net loss of $22,271 thousand, compared with $13,779 thousand a year earlier. Net loss per share was $0.76, compared with $3.44. No collaboration Revenue was recognized, compared with $360 thousand.

Research and development expenses were $20,290 thousand, compared with $12,317 thousand, and general and administrative expenses were $4,734 thousand, compared with $3,645 thousand. The company attributed the Research and Development increase primarily to higher clinical, Manufacturing and preclinical services of $7.2 million. Interest income was $2,787 thousand, compared with $1,855 thousand.

For the nine months ended September 30, 2026, the net loss was $61,614 thousand, compared with $43,369 thousand, collaboration revenue was $450 thousand, compared with $360 thousand, and research and development expenses were $55,982 thousand, compared with $37,761 thousand. The accumulated Deficit was $172.6 million at September 30, 2026.

Balance Sheet and Cash Flow

At September 30, 2026, cash and cash equivalents were $115,366 thousand, compared with $40,193 thousand at December 31, 2025, and marketable securities were $280,573 thousand, compared with $112,075 thousand. Total Assets were $411,824 thousand and total liabilities were $14,083 thousand. For the nine months, net cash used in Operating Activities was $60,602 thousand and net cash provided by financing activities was $306,160 thousand.

Pipeline and Outlook

ATTO-1310 completed dosing in a Phase 1 trial with volunteers and patients in the first quarter of 2026. The company expects to commence a Phase 1 trial of ATTO-2306 in the first half of 2027. ATTO-1091 is in IND-enabling studies and, subject to IND clearance, is expected to enter Phase 1 in the first half of 2027. The company has no products approved for sale.

Attovia said it expects its expenses and Capital requirements to increase. Based on its current operating plan, it estimates that its cash, cash equivalents and marketable securities will be sufficient to fund projected operating expenses and Capital Expenditure requirements into 2030. It also said it will require additional capital and that equity financings could dilute stockholders.